Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 30, 2025 07:55 ET | Source: Clearmind Medicine Inc.

Clearmind Medicine Completes First Cohort Treatment in its FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder

Milestone advances MEAI-based therapy targeting a global Alcohol Use Disorder treatment market projected to surpass $20 billion by 2032 Vancouver, Canada, Oct. 30, 2025 (GLOBE NEWSWIRE) -- ...
July 15, 2025 08:05 ET | Source: Clearmind Medicine Inc.

Clearmind Expands its Clinical Trial for Alcohol Use: New Site Activated and Additional Participant Enrolled

Vancouver, Canada, July 15, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and...
July 09, 2025 06:15 ET | Source: Research and Markets

Alcohol Use Disorder Market Report 2025-2035 Featuring Clearmind Medicine, Purdue Pharma, Psyence Biomedical, Eli Lilly and Co, Tempero Bio,, Nxera Pharma, Novo Nordisk, Adial, Alkermes, Lundbeck

Dublin, July 09, 2025 (GLOBE NEWSWIRE) -- The "Alcohol Use Disorder Market - A Global and Regional Analysis: Focus on Regional and Country Analysis - Analysis and Forecast, 2025-2035" report has...
July 03, 2025 08:47 ET | Source: Clearmind Medicine Inc.

Clearmind Medicine Announces IRB Approval for Phase 1/2a Clinical Trial for Alcohol Use Disorder at Tel Aviv Sourasky Medical Center

Vancouver, Canada, July 03, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and...
June 27, 2025 09:00 ET | Source: Clearmind Medicine Inc.

Clearmind Medicine Expands Global Clinical Trial Targeting Multibillion-Dollar Alcohol Use Disorder Market

Vancouver, Canada, June 27, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and...
June 25, 2025 07:48 ET | Source: Clearmind Medicine Inc.

Clearmind Medicine Enrolls First Patient in its Clinical Trial for Alcoholism Treatment

CMND-100 has the potential to provide an innovative and advanced treatment option for hundreds of millions of people around the world afflicted with Alcohol Use Disorder Vancouver, Canada, June 25,...
May 29, 2025 07:33 ET | Source: Research and Markets

Alcohol Use Disorder (AUD) Market Trends and Forecasts (2025-2030) by Drug Class, Treatment Type, End User, Distribution Channel, Formulation, Region and Country

Dublin, May 29, 2025 (GLOBE NEWSWIRE) -- The "Alcohol Use Disorder Market by Drug Class, Treatment Type, End User, Distribution Channel, Formulation - Global Forecast to 2030" report has been added...
December 17, 2024 15:30 ET | Source: Laguna Treatment Center

Laguna Treatment Center Launches Tribal Recovery Track, Expanding Culturally Competent Care for Native Americans

With more than 100 federally recognized Native American tribes in California alone, Laguna Treatment Center is adding a new tribal recovery track.
July 16, 2024 09:02 ET | Source: Clearmind Medicine Inc.

Clearmind Medicine Obtains IND Approval from the FDA to Start the Phase I/IIa Clinical Trial with its Innovative Treatment for Alcoholism

Vancouver, Canada, July 16, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and...
June 21, 2024 09:22 ET | Source: Research and Markets

Disulfiram Presents a $521+ Million Industry Opportunity by 2030: Increasing Patient Awareness and Higher Treatment-Seeking Rate

Dublin, June 21, 2024 (GLOBE NEWSWIRE) -- The "Global Disulfiram Market by Indication (Alcoholism Treatment, Co-occurring Disorders), Distribution Channel (Hospital Pharmacies, Online Pharmacies,...